As stated earlier, cardiotoxic HF patients currently receive the same standard treatment for HF that focuses on reversing external symptoms rather than targeting underlying causes (e.g., in cases of reduced LVEF, enhancing LVEF through a reduction of arterial tension by β blockers and ACE inhibitors) (7). The gene discussed is ACE; the disease is hydrops fetalis.